Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19 (GlobeNewswire, Akers Biosciences Inc.) - Apr 6, 2020 - "Successfully obtained clones for all three selected Coronavirus Antigens. Thorofare, New Jersey, April 06, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate."
Clinical
|